J Allergy Clin Immunol: Patients with high IL-17 asthma have psoriasis immunotypes.

The role of IL-17 immunity in patients with inflammatory diseases such as psoriasis and inflammatory bowel disease has been fully recognized, but its role in asthma patients is not obvious and needs further study.
study, which aims to conduct an in-depth esologic study of asthma patients with il-17 immunity, was published online at J Allergy Clin Immunol.
A genome-wide transcription group analysis was performed using skin brush tablets, bronchial biopsy specimens (91 asthma patients and 46 healthy control group subjects) and whole blood samples (n s 498) from u-BIOPRED queues that predict respiratory disease outcomes.
used in-body induced genetic markers of IL-17 and IL-13 in bronchial endotment cells to identify patients with IL-17 high and IL-13 high asthma esoteric.
results, 22 out of 91 patients and 9 patients were identified with IL-17 and IL-13 gene markers.
high IL-17 asthma patients are characterized by frequent seizures, increased neutral granulocytes in the air (sputum and mucous membranes), reduced diversity of the lung microbiome, and the risk of urine biomarkers activated by the thrombosis B2 pathway.
In pathline analysis, genes expressed differently in patients with high IL-17 asthma had something in common with genes that altered skin loss in psoriasis, including genes that regulate the function and defense mechanisms of the endotment barrier, such as IL1B, IL6, IL8, and β-defenses.
, the results show that the high IL-17 asthma ideotope, characterized by bronchial endocrine dysfunction and an increase in antibacterial and inflammatory responses, is similar to the immunoshapype of psoriasis, including the activation of the thrombosis B2 pathline, and should be considered a biomarker of the ideology in further studies, including clinical trials of IL-17.
.